The Einstein line of allograft bone includes an Inductive Bone Matrix (IBM), a Demineralized Bone Matrix (DBM) and a Compressive Bone Scaffold (CBS). All Einstein products are 100% human bone and are verified for osteoinductivity post-sterilization prior to release for distribution. Wizard is a line of synthetic bone-graft substitutes comprised of beta-tricalcium phosphate (TCP) granules and a calcium phosphate (CAP) flowable cement.
Reinvent Biologics CEO Bryant Gaines highlights, “The Genius Concentration System product line has been expanded to include a larger-capacity option for the processing of blood and bone-marrow aspirate. “When we launched the company last year, our testing indicated we could deliver more viable components from 30mL of blood and bone-marrow aspirate than many devices did from 60mL.” Gaines added, “As interest in using biologics to augment bone healing continues to increase, it makes sense to accommodate physician demand for higher output volume. The addition of a variety of allograft and synthetic scaffolds allows the physician the option of selecting what is best for each situation – and it provides our distributors another tool in their sales bag.”
Last year, the company introduced the Genius Concentration System, which utilizes a unique vertical centrifugation design for processing blood and bone marrow aspirate. Through these biologics-based product portfolio extensions, Reinvent Biologics is poised to further penetrate the growing biologics market. A recent market research report predicted the global orthopedic biologics market could reach $5.8 billion by 2018, with a compounded annual growth rate of 5.9%. Due to the highly fragmented landscape, the team at Reinvent believes there is great potential for a company offering “game-changing” products. Reinvent Biologics distributes its products through a network of independent distributors.